CTA
VRTX icon

Colonial Trust Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Colonial Trust Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Buy
237
+64
+37% +$29.8K 0.01% 266
2025
Q4 		$78.4K Sell
173
-50
-22% -$21.6K 0.01% 297
2025
Q3 		$87.3K Buy
223
+13
+6% +$5.43K 0.01% 276
2025
Q2 		$93.5K Hold
210
– – 0.01% 266
2025
Q1 		$102K Buy
210
+50
+31% +$23.3K 0.01% 258
2024
Q4 		$64.4K Hold
160
– – 0.01% 285
2024
Q3 		$74.4K Sell
160
-100
-38% -$48K 0.01% 291
2024
Q2 		$122K Sell
260
-19
-7% -$8.25K 0.01% 229
2024
Q1 		$117K Buy
279
+3
+1% +$1.27K 0.01% 230
2023
Q4 		$112K Buy
276
+245
+790% +$90.5K 0.01% 227
2023
Q3 		$10.8K Hold
31
– – ﹤0.01% 505
2023
Q2 		$10.9K Buy
31
+15
+94% +$5.05K ﹤0.01% 513
2023
Q1 		$5.04K Sell
16
-5
-24% -$1.5K ﹤0.01% 618
2022
Q4 		$6.06K Buy
+21
New +$6.4K ﹤0.01% 589

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Colonial Trust Advisors's VRTX Position: Q1 2026 in Review

Colonial Trust Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 37% in Q1 2026, buying an estimated $29.8K and bringing the position to 237 shares worth $106K. The position accounts for 0.01% of the portfolio, ranked #266.

Colonial Trust Advisors first reported a position in VRTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $122K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Colonial Trust Advisors held 237 shares of Vertex Pharmaceuticals worth $106K as of Q1 2026.
  • Colonial Trust Advisors bought 64 Vertex Pharmaceuticals shares in Q1 2026, an estimated $29.8K.
  • Vertex Pharmaceuticals made up 0.01% of Colonial Trust Advisors's portfolio in Q1 2026, its #266 holding.
  • Colonial Trust Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Colonial Trust Advisors's Vertex Pharmaceuticals position peaked at $122K in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Colonial Trust Advisors's 13F filing for Q1 2026, filed 12 May 2026.